A compassionate access protocol to assess the safety of xolair (omalizumab) in patients (greater than or equal to 6 years old) with severe allergic asthma who remain symptomatic despite optimal therapy

Trial Profile

A compassionate access protocol to assess the safety of xolair (omalizumab) in patients (greater than or equal to 6 years old) with severe allergic asthma who remain symptomatic despite optimal therapy

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Oct 2016

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Asthma
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 23 May 2012 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
    • 27 Oct 2011 Planned End Date changed from 1 Dec 2008 to 1 Dec 2011 as reported by ClinicalTrials.gov.
    • 03 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top